BRKR
Bruker Corporation
BRKR's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over BRKR overall, supported by stronger fundamentals and lower modeled downside.
BRKR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Healthy | |
| Weak |
BRKR's cash flow is currently healthy, and its revenue is stable, but its profitability and balance sheet are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
BRKR PE Valuation
BRKR has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
BRKR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect BRKR's earnings to grow and its profitability to improve, with its revenue holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over BRKR on the outlook, with more favorable revenue expectations.
BRKR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.34 | — |
| Q3 2026 | -$1.10 | -$0.94 |
| Q2 2026 | -$0.70 | -235% |
| Q1 2026 | -$0.24 | -146% |
| Q4 2025 | -$0.15 | -120% |
| Q3 2022 | $1.82 | +3.4% |
| Q2 2022 | $1.80 | +17% |
| Q1 2022 | $1.85 | +40% |
| Q4 2021 | $1.81 | +77% |
BRKR lost $1.10 per share over the past year, and its loss has widened in each of the last three quarters.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over BRKR on earnings quality, reporting a profit while its opponent remains loss making.
BRKR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $874M | +1.6% |
| Q2 2026 | $838.5M | +5.2% |
| Q1 2026 | $823.4M | +2.7% |
| Q4 2025 | $977.2M | -0.2% |
| Q3 2025 | $860.5M | -0.5% |
| Q2 2025 | $797.4M | -0.4% |
| Q1 2025 | $801.4M | +11% |
| Q4 2024 | $979.6M | +15% |
BRKR's revenue grew through 2024 and has held roughly level since: $874M last quarter, up 1.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -10% | -4.4 points |
| Q2 2026 | -7.8% | -9.3 points |
| Q1 2026 | 1.2% | -2.7 points |
| Q4 2025 | 7.8% | +0.4 points |
| Q3 2025 | -6% | -14 points |
| Q2 2025 | 1.5% | -4.5 points |
| Q1 2025 | 4% | -5 points |
| Q4 2024 | 7.4% | -4.7 points |
BRKR's operating margin was −10% last quarter, down 4.4 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over BRKR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over BRKR on profitability, with a higher operating margin.
BRKR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $96.7M | +$150.8M |
| Q2 2026 | -$106.2M | +$42.6M |
| Q1 2026 | $47M | +21% |
| Q4 2025 | $207.2M | +35% |
| Q3 2025 | -$54.1M | -1033% |
| Q2 2025 | -$148.8M | -$125.3M |
| Q1 2025 | $39M | +9650% |
| Q4 2024 | $153.3M | -12% |
BRKR's free cash flow has turned positive again: $245M over the past year, against −$11M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over BRKR on cash flow, with more consistent year-over-year improvement.
BRKR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +200K shares |
| 1 year | +0.5% | +700K shares |
| 3 years | -1.9% | -2.9M shares |
BRKR has 153M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $10M |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over BRKR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
BRKR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 10.0x | High |
| Q2 2026 | 8.2x | High |
| Q1 2026 | 5.6x | High |
| Q4 2025 | 5.4x | High |
| Q3 2025 | 6.2x | High |
| Q2 2025 | 5.9x | High |
| Q1 2025 | 4.6x | High |
| Q4 2024 | 4.4x | High |
BRKR's net debt is about 10 years of its operating earnings (EBITDA), up from 6.2 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over BRKR on leverage, with a lower net debt burden relative to earnings.
BRKR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.3 | Neutral |
| Stochastic | 52.9 | Neutral |
BRKR's weekly RSI is 55 (neutral) and its Stochastic is 53 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
BRKR PE vs Healthcare Sector
| Metric | BRKR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
BRKR has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
BRKR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $59.7 | 1.1% above |
| 20 week MA | $59.1 | 2.1% above |
| 50 week MA | $50.4 | 20% above |
| 100 week MA | $46.4 | 30% above |
| 200 week MA | $58.3 | 3.6% above |
BRKR has climbed back above all five of its weekly moving averages, and it's now 3.6% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
BRKR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.0 | $54.3 | +6.6% |
| 2021 | $54.3 | $80.3 | +48% |
| 2022 | $80.3 | $66.5 | -17% |
| 2023 | $66.5 | $73.5 | +10% |
| 2024 | $73.5 | $58.4 | -21% |
| 2025 | $58.4 | $48.0 | -18% |
| 2026 YTD | $48.0 | $60.3 | +26% |
BRKR has finished lower in three of the last six years. It's up 26% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over BRKR on returns for 2026, with the stronger performance.